陇神戎发前三季度扣非净利润同比增逾三成 核心产品市场竞争力不断提升

Core Viewpoint - Gansu Longshen Rongfa Pharmaceutical Co., Ltd. reported steady growth in revenue and net profit for the first three quarters of 2025, driven by the recovery of the traditional Chinese medicine industry and the enhancement of its core product competitiveness [1][2]. Financial Performance - The company achieved an operating income of 647 million yuan and a net profit attributable to shareholders of 27.03 million yuan, representing a year-on-year increase of 8.11% [1]. - The net profit excluding non-recurring gains and losses was 28.71 million yuan, up 31.14% year-on-year [1]. Market Position and Product Development - Longshen Rongfa has focused on optimizing its market sales layout, consolidating the market share of its core products, and exploring the market potential of existing generic drugs [2]. - The company’s two exclusive products, Yuanhu Zhitong Pill and Xuanfei Zhike Mixture, have seen increased market competitiveness and brand influence, ranking in the top 20 for various categories in public medical institutions [2]. Production Capacity and R&D - A new production line for the Xuanfei Zhike Mixture has been established, capable of producing 50 million boxes annually, ensuring a solid supply for the market [3]. - The company emphasizes product R&D as a core driver of sustainable development, with ongoing projects for product development and clinical trials [3]. Future Outlook - The company plans to continue focusing on traditional Chinese medicine, enhancing market development and research efforts to promote sustainable growth [3].